본문바로가기

About

Integrate AI and the human intelligence to optimize patient outcomes

About Deep Bio
Deep Bio was founded with the transformative mission: To advance patient outcomes by driving innovation in technology, while empowering clinicians by providing the tools to make critical decisions. We envision a world where clinicians are empowered with technology designed to unlock personalized insights and enhance healthcare delivery, so they can focus more on what they do best: caring for their patients.

Solving Medical Unmet Needs with the Power of AI

Challenges
Pathology is a field of medicine where specimen samples such as organ, body tissue, or body fluids are examined to diagnose presence and severity of disease including cancer. In current practice, pathologists examine glass slides of processed specimens, using microscopes.
  • Step 1Biopsy is performed on a patient with clinical suspicion of cancer
  • Step 2Tissue specimen is processed, mounted and stained on glass slides for examination
  • Step 3A pathologist examines the glass slides on a microscope and issues a final diagnosis
    that determine the follow up and treatment care for the patient
  • Step 1Prostate needle biopsy is performed on a patient with clinical suspicion of prostate cancer
  • Step 2Tissue specimen is processed, mounted and stained on glass slides for examination
  • Step 3A pathologist examines the glass slides on a microscope and issues a diagnosis
    based on the Gleason Scoring System

Major Challenges 1

Shortage of pathologists and the resultant increase in workload

In the US, the number of active pathologists dropped by 18% from 2007 to 2017. In South Korea, only 7 graduates enrolled in pathology residency where 65 slots were available in 2020.

Major Challenges 2

Discordance among pathologists in diagnosis

With varying levels of talent and experience, pathologists notice different things and have different perspectives on what is important which results in inconsistency and discordance among pathologists in diagnoses.

Technology
We are a world leader in technological capability based in deep learning algorithm.

Innovation
Since its establishment, Deep Bio has committed to integrating state-of-the-art technology into clinical workflows for improved patient care.

Transformation
Our in-house medical experts and machine learning engineers combine their domain knowledge to bring the AI-driven transformation in the field of medicine.

Evidence
Deep Bio has retained its No.1 position in the Camelyon Challenge (Global image analysis competition for categorizing lymph node metastasis) since its first submission in 2018.
Solutions
Dedicated in tackling the challenges in pathology and improving diagnostic workflow, Deep Bio is developing and implementing deep learning-based cancer diagnostic support software.
DeepDx
Our AI digital pathology is the solution to stay ahead. Deep Bio’s AI-powered solution, DeepDx, empowers pathologists to become more accurate and consistent when making critical diagnostic decisions for cancer. By improving the reliability of diagnosis while decreasing turnaround times, Deep Bio aims to optimize digital pathology workflows to make quality healthcare more accessible across the globe.

Benefits of using DeepDx

Benefit 1

Accuracy in quantifying the areas of interest in ratios

Benefit 2

Quality check for any potential missed areas of interest

Benefit 3

Consistency and reproducibility of diagnoses

Deep Bio’s deep learning-based cancer diagnostic support software minimizes the risk of human error from manual handling and subjectivity of pathologist assessment resulting in decreased turnaround time, more precise and consistent diagnostic results, and improved reproducibility. Precise classification and quantification of different morphological patterns and cells offer new insights and relationships that can help medical professionals optimize their decisions and determine the best treatment options for patients.

Management

We are a team dedicated to innovating traditional healthcare

Sun Woo Kim
Chief Executive Officer

Sun Woo Kim, the founder and CEO of Deep Bio Inc., has a proven track record of over 20 years in executive management as well as computer science expertise. He founded Deep Bio based on the firm belief that AI can revolutionize healthcare and address some of the existing challenges, starting with improved diagnostic processes. Prior to founding Deep Bio, he served as the Chief Technology Officer of Pinion Industries, an automotive software and security start-up, which was acquired by Hyundai Motors in 2014. He was also the deputy director of Korea Telecommunications, the largest telecommunications company in Korea, where he led the global venture capital team.

Tae Yeong Kwak
Chief Technical Officer

Tae Yeong Kwak has unmatched expertise across a span of computer programming subspecialties, including algorithm design, computer systems design, and big data analysis. Prior to joining Deep Bio, he was at Netmarble, Korea’s biggest mobile gaming company, where he directed their AI Lab and also managed big data analysis and systems operations. At Naver Corporation, the first company in Korea to launch an online platform, he led the natural language processing machine learning team.

Hoi Chang Chung
Chief Finance Officer

Hoi Chang Chung is KICPA certified, and as the Chief Financial Officer, has contributed to overseeing all financial accounts and coordinating audit activities of Deep Bio. Before joining Deep Bio, Hoi Chang Chung was the Head of Finance at companies in diverse industries including pharmaceutical, insurance, education and finance. He has extensive experience in managing finance, fund raising, budgeting and IPO preparations.

Yoon Min Lee
Chief Business Officer

Yoon Min Lee is a US expat living in Korea since 2011. He brings more than 15 years of experience in global business development. He holds an MBA from UCLA Anderson School of Management and a BS from UC Berkeley Haas School of Business. He has previously worked in diverse industries including advanced materials, high-tech displays, and medical AI solutions. He contributes his extensive BD experience from having worked at both startups as well as top Korean multi-nationals such as Samsung.

Yong Hyun Hwang
Chief Architect Officer

Yong Hyun Hwang has over 20 years of experiences working for multinational companies such as Google, Microsoft, Qualcomm, and Oracle as a software engineer and a researcher. Yong Hyun Hwang holds extensive knowledge, capability and experiences in innovating, architecting and designing new infrastructures and toolsets to improve existing workflow and developer proficiency. At Google, he led and completed a project that saves Google data center more than $150 million per year.

Hye Yoon Chang
Medical Officer

Dr. Hye Yoon Chang, Deep Bio’s Medical Officer, brings more than twenty years of experience as a board-certified pathologist specializing in anatomic pathology. She holds a medical degree and a Ph.D. from Korea University, the nation’s top institution in medical research, where she also completed her residency. Hye Yoon has authored numerous papers on ground-breaking research in clinical pathology and serves as a member of the Korean Pathology Society and Korean Cytology Society.